Trial Profile
A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Imlifidase (Primary)
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Acronyms Highdes
- Sponsors Hansa Biopharma AB
- 08 Jul 2021 Results of pooled analysis assessing 3 years post transplant from 13 HMedIdeS02, 13HMedIdeS03, 14HMedIdeS04 15HMedIdeS06 and 17HMedIdeS14 published in the American Journal of Transplantation.
- 12 Oct 2020 Results published in the Transplantation
- 26 Aug 2020 According to a Hansa Biopharma AB media release, the European Commission has granted conditional approval for IdefirixTM in highly sensitized kidney transplants patients.